China’s Ultra-Cheap EV Boom: Why Electric Cars Cost Far Less Than in the U.S. 
Samsung Reports Record Profit as AI Boom Drives Memory Chip Demand 
Microsoft Azure Growth Forecast Beats Expectations Amid Rising AI Competition 
OpenAI Faces Revenue Pressure and User Growth Challenges Ahead of IPO 
AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales 
Seagate Stock Surges After Strong Q3 Earnings Beat and Bullish Outlook 
Ford Q1 Earnings Beat Expectations, Stock Surges on Strong Guidance 
TSMC Exits Arm Holdings with $231 Million Share Sale Amid Strategic Portfolio Shift 
Micro Systemation Reports Q1 Loss Amid Strategic Investments and Revenue Growth 
Google Secures Pentagon AI Deal for Classified Projects 
Starbucks Raises 2026 Outlook as Turnaround Strategy Boosts Sales and Earnings 
Spirit Airlines Gains Key Creditor Support for $500M Bailout Deal 
Coles Group Q3 Sales Rise Driven by Supermarkets and E-Commerce Growth 
Why Paycom Was Named a 2026 Platinum Employer on the Where You Work Matters List 
T-Mobile Beats Q1 Earnings Expectations on Strong Postpaid Growth 
Air Liquide Q1 Revenue Misses Estimates Amid Currency and Energy Headwinds 
MALVERN, Pa., April 24, 2017 -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a dermatologist-led biotechnology company focused on defining new standards of care in medical and aesthetic dermatology, today announced it will sponsor a symposium on Janus Kinase (JAK) inhibitors at the 76th Annual Society for Investigative Dermatology Meeting in Portland, Oregon. The symposium, titled “You Don’t Know JAK,” will be held on Thursday, April 27, 2017, from 12:00-1:45 PM PST. Poster presentations include:
- Clinical investigation of JAK inhibitor tofacitinib in scarring alopecias: Lindsey Bordone, MD, Columbia University, New York, NY, Abstract #075
- Treatment of vitiligo with topical Janus Kinase inhibitor ruxolitinib: Brooke Rothstein, Tufts Medical Center, Boston, MA, Abstract #770
- Predictive modeling of drug response and mechanism of action in alopecia areata clinical trials: James Chen, PhD, Columbia University, New York, NY, Abstract #397
Dr. Neal Walker, President and Chief Executive Officer, and Dr. Stuart Shanler, Chief Scientific Officer, will be in attendance. Following the poster presentations, there will be a panel discussion and question and answer session with presenters.
Additional information on the 76th Annual Society of Investigative Dermatology Meeting can be found at: http://www.sidnet.org/news/339026/View-the-2017-Annual-Meeting-Program.htm
About Aclaris Therapeutics, Inc.
Aclaris Therapeutics, Inc. is a dermatologist-led biotechnology company focused on identifying, developing and commercializing innovative and differentiated therapies to address significant unmet needs in medical and aesthetic dermatology. Aclaris is based in Malvern, Pennsylvania.
Contact: Aclaris Contact Michael Tung, M.D. Investor Relations 484-329-2140 [email protected] Media Contact Mariann Caprino TogoRun 917-242-1087 [email protected]
